Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948946 · ClinicalTrials.gov registry record
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
A clinical trial, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- 105
- Enrollment target
NCT02948946 is a clinical trial that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 105 participants.
The verdict
NCT02948946 has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
Interventions
- PROCEDURE NETest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-01-09 |
| Est. Completion | 2020-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948946
The ClinicalTrials.gov registry entry for NCT02948946 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NETest is the first listed.
NCT02948946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948946 about?
NCT02948946 is a clinical study titled "Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors". The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
What is the current status of trial NCT02948946?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2017-01-09. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT02948946?
The interventions under investigation include: NETest (PROCEDURE).
Who is sponsoring clinical trial NCT02948946?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.